Literature DB >> 29091259

Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer.

K Polom1,2, L Marano3, D Marrelli1, R De Luca4, G Roviello5,6, V Savelli1, P Tan7, F Roviello1.   

Abstract

BACKGROUND: Several associations between microsatellite instability (MSI) and other clinicopathological factors have been reported in gastric cancer, but the results have been ambiguous. This systematic review and meta-analysis investigated the relationship between MSI and overall survival and clinicopathological characteristics of patients with gastric cancer.
METHODS: A systematic literature search of the PubMed, Cochrane and Ovid databases until 31 January 2016 was performed in accordance with the PRISMA statement. The articles were screened independently according to PICO (population, intervention, comparator, outcome) eligibility criteria. All eligible articles were evaluated independently by two reviewers for risk of bias according to the Quality In Prognosis Study tool.
RESULTS: Overall, 48 studies with a total of 18 612 patients were included. MSI was found in 9·2 per cent of patients (1718 of 18 612), and was associated with female sex (odds ratio (OR) 1·57, 95 per cent c.i. 1·31 to 1·89; P < 0·001), older age (OR 1·58, 2·20 to 1·13; P < 0·001), intestinal Laurén histological type (OR 2·23, 1·94 to 2·57; P < 0·001), mid/lower gastric location (OR 0·38, 0·32 to 0·44; P < 0·001), lack of lymph node metastases (OR 0·70, 0·57 to 0·86, P < 0·001) and TNM stage I-II (OR 1·77, 1·47 to 2·13; P < 0·001). The pooled hazard ratio for overall survival of patients with MSI versus those with non-MSI gastric cancer from 21 studies was 0·69 (95 per cent c.i. 0·56 to 0·86; P < 0·001).
CONCLUSION: MSI in gastric cancer was associated with good overall survival, reflected in several favourable clinicopathological tumour characteristics.
© 2017 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29091259     DOI: 10.1002/bjs.10663

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  69 in total

1.  Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial.

Authors:  Maria Di Bartolomeo; Federica Morano; Alessandra Raimondi; Rosalba Miceli; Salvatore Corallo; Elena Tamborini; Federica Perrone; Maria Antista; Monica Niger; Alessandro Pellegrinelli; Giovanni Randon; Filippo Pagani; Antonia Martinetti; Giovanni Fucà; Filippo Pietrantonio
Journal:  Oncologist       Date:  2019-11-25

2.  Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial.

Authors:  Maria Di Bartolomeo; Federica Morano; Alessandra Raimondi; Rosalba Miceli; Salvatore Corallo; Elena Tamborini; Federica Perrone; Maria Antista; Monica Niger; Alessandro Pellegrinelli; Giovanni Randon; Filippo Pagani; Antonia Martinetti; Giovanni Fucà; Filippo Pietrantonio
Journal:  Oncologist       Date:  2019-11-25

Review 3.  Clinical impact of molecular classifications in gastric cancer.

Authors:  Daniele Marrelli; Karol Polom; Alessandro Neri; Franco Roviello
Journal:  Updates Surg       Date:  2018-05-23

Review 4.  Translational research and application of basic biology to clinical trial development in GI cancers.

Authors:  Elizabeth Smyth; Khurum Khan; Nicola Valeri
Journal:  Ann Transl Med       Date:  2018-05

Review 5.  Clinical characteristics and responses to chemotherapy and immune checkpoint inhibitor treatment for microsatellite instability gastric cancer.

Authors:  Guang Yang; Ru-Yi Zheng; Qiang Tan; Cheng-Ji Dong; Zai-Shun Jin
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

6.  Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched.

Authors:  Chun-Yi Tsai; Tien-An Lin; Shih-Chiang Huang; Jun-Te Hsu; Chun-Nan Yeh; Tse-Ching Chen; Cheng-Tang Chiu; Jen-Shi Chen; Ta-Sen Yeh
Journal:  Oncologist       Date:  2020-02-14

7.  High immune cell score predicts improved survival in pancreatic cancer.

Authors:  Kyösti Tahkola; Jukka-Pekka Mecklin; Erkki-Ville Wirta; Maarit Ahtiainen; Olli Helminen; Jan Böhm; Ilmo Kellokumpu
Journal:  Virchows Arch       Date:  2018-01-22       Impact factor: 4.064

8.  Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1.

Authors:  Marina Alessandra Pereira; Marcus Fernando Kodama Pertille Ramos; André Roncon Dias; Sheila Friedrich Faraj; Renan Ribeiro E Ribeiro; Tiago Biachi de Castria; Bruno Zilberstein; Venancio Avancini Ferreira Alves; Ulysses Ribeiro; Evandro Sobroza de Mello
Journal:  Mol Diagn Ther       Date:  2019-12       Impact factor: 4.074

9.  A polymorphism within the mismatch repair gene predicts prognosis and adjuvant chemotherapy benefit in gastric cancer.

Authors:  Xiaohui Zhao; Dongfang Dai; Xiaoqin Li; Bo Shen; Xiaofeng Chen; Yongqian Shu; Deqiang Wang
Journal:  Gastric Cancer       Date:  2019-04-15       Impact factor: 7.370

Review 10.  Challenges surrounding postoperative adjuvant chemotherapy for T2N0 gastric cancer.

Authors:  Ke-Kang Sun; Qing-Hua Wang; Yong-You Wu
Journal:  Oncol Lett       Date:  2020-08-19       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.